<DOC>
	<DOCNO>NCT00742924</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This clinical trial study side effect best dose zoledronic acid give together combination chemotherapy treat patient newly diagnose metastatic osteosarcoma .</brief_summary>
	<brief_title>Zoledronic Acid Combination Chemotherapy Treating Patients With Newly Diagnosed Metastatic Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary : - To assess feasibility safety zoledronic acid administer combination standard chemotherapy patient newly diagnose metastatic osteosarcoma . - To determine maximum tolerate dose zoledronic acid administer combination standard chemotherapy patient . Secondary : - To compare histologic response event-free survival patient treat regimen versus patient treat INT-0133 CCG-7943 . OUTLINE : This multicenter , dose-escalation study zoledronic acid . - Induction therapy ( week 1-11 ) : Patients receive dexrazoxane hydrochloride IV slowly 5-15 minute , doxorubicin hydrochloride IV 15 minute , cisplatin IV 1 hour day 1 2 week 1 6 ; zoledronic acid IV assign dose level 30 minute day 4 week 1 6 ; high-dose methotrexate IV 4 hour day 1 week 4 , 5 , 9 , 10 ; leucovorin calcium IV orally every 6 hour start day 2 continue clearance methotrexate week 4 , 5 , 9 , 10 ; filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 3 week 1 6 continue blood count recover . - Surgery ( week 12 ) : Patients undergo definitive surgery ( limb-salvage surgery amputation ) primary tumor week 12 . - Maintenance therapy course 1 ( week 13-25 ) : Patients receive etoposide IV 1 hour ifosfamide IV 4 hour day 1-5 week 13 21 ; zoledronic acid IV 30 minute day 4 week 17 day 7 week 13 21 ; high-dose methotrexate IV 4 hour day 1 week 16 , 20 , 24 ; leucovorin calcium IV orally every 6 hour start day 2 continue clearance methotrexate week 16 , 20 , 24 ; dexrazoxane hydrochloride IV slowly 5-15 minute , doxorubicin hydrochloride IV 15 minute , cisplatin IV 1 hour day 1 2 week 17 ; G-CSF SC daily begin day 6 week 13 , 17 , 21 continue blood count recover . - Surgery ( week 26 ) : Patients may undergo surgical resection primary metastasis week 26 . - Maintenance therapy course 2 ( week 27-36 ) : Patients receive dexrazoxane hydrochloride IV slowly 5-15 minute doxorubicin hydrochloride IV 15 minute day 1 2 week 27 31 ; cisplatin IV 1 hour day 1 2 week 27 ; zoledronic acid IV 30 minute day 4 week 27 day 7 week 31 36 ; high-dose methotrexate IV 4 hour day 1 week 30 , 34 , 35 ; leucovorin calcium IV orally every 6 hour start day 2 continue clearance methotrexate week 30 , 34 , 35 ; etoposide IV 1 hour day 1-5 week 36 ; ifosfamide ( 1.8 gm/m2 ) IV 1 hour day 1-5 week 31 ; ifosfamide ( 2.8 gm/m2 ) IV 4 hour day 1-5 week 36 ; G-CSF SC daily begin day 3 week 27 , 31 , 36 continue blood count recover . Mensa supportive care medicine use prevent hemorrhagic cystitis cause ifosfamide . It always give ifosfamide give . It use arm . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven highgrade osteosarcoma within past 6 week Newly diagnose disease Metastatic disease Resectable disease OR expect become resectable initial chemotherapy Disease arise outside area Paget 's disease PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 50100 % ( patient &gt; 16 year age ) OR Lansky PS 50100 % ( patient ≤ 16 year age ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR maximum serum creatinine base age/gender follow : 0.4 mg/dL ( patient 1 5 month age ) 0.5 mg/dL ( patient 6 11 month age ) 0.6 mg/dL ( patient 1 year age ) 0.8 mg/dL ( patient 2 5 year age ) 1 mg/dL ( patient 6 9 year age ) 1.2 mg/dL ( patient 10 12 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient 13 15 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient ≥ 16 year age ) Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age Shortening fraction ≥ 28 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ ( transfusion independent ) Hemoglobin ≥ 10 g/dL ( RBC transfusion allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use contraception No known HIV infection No history pericarditis , myocarditis , symptomatic arrhythmia , conduction disturbance PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No concurrent anticancer chemotherapy No concurrent immunomodulating agent Steroids antiemetic allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
</DOC>